Sanofi: US FDA approves Cablivi
(CercleFinance.com) - Sanofi announces that the US Food and Drug Administration (FDA) has approved Cablivi (caplacizumab-YHDP), in combination with plasma and immuno-suppressive therapy, in the treatment of acquired thrombotic purpura thrombocytopenic (PTT) in adults.
Cablivi is the first drug specifically approved by the FDA for the
treatment of acquired PTT.
Cablivi targets the von Willebrand factor (vWF), a blood protein
involved in hemostasis. It is designed to inhibit the interaction
between vWF and platelets.
In this US, acquired PTT affects around 2,000 adults each year.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
Cablivi is the first drug specifically approved by the FDA for the
treatment of acquired PTT.
Cablivi targets the von Willebrand factor (vWF), a blood protein
involved in hemostasis. It is designed to inhibit the interaction
between vWF and platelets.
In this US, acquired PTT affects around 2,000 adults each year.
Copyright (c) 2019 CercleFinance.com. All rights reserved.